PMID: 8614273Jan 1, 1996Paper

Safety/tolerability trial of SDZ ENA 713 in patients with probable Alzheimer's disease

Life Sciences
J J SramekN R Cutler

Abstract

SDZ ENA 713 (ENA 713) is an acetylcholinesterase inhibitor being developed as a potential treatment for Alzheimer's disease (AD). A prior Phase II safety and efficacy study used an upper dose limit of 6 mg/day ENA 713. The present study was designed to assess the safety and tolerability of higher doses of ENA 713 in probable AD patients. Fifty AD patients (22M; 28F, mean age 68 yrs, range 45-90) were assigned to a fixed, nine-week dose escalation schedule in which they were randomized to receive up to 12 mg/day of ENA 713 bid (n=20) or tid (n=20), or placebo (n=10) followed by a one-week washout. Mg/day dose escalation for the bid and tid ENA 713 groups was identical, beginning with 2 mg/day on Days 1 to 3 and escalating to 12 mg/day in Weeks 8 and 9. Doses through 12 mg/day were well tolerated. Most adverse events were mild to moderate in severity and of limited duration, most commonly headache, nausea, dizziness, and diarrhea. Three of forty patients on ENA 713 discontinued, all due to adverse events. Two experienced nausea and vomiting; the third experienced an unrelated mild atrial fibrillation.

Citations

Apr 29, 1998·Journal of Clinical Pharmacology·N R CutlerR L Williams
Dec 29, 2000·Disease-a-month : DM·D S Knopman
Dec 16, 1998·European Journal of Pharmacology·E LazartiguesO Rascol
Mar 27, 2001·Progress in Neuro-psychopharmacology & Biological Psychiatry·N R Cutler, J J Sramek
Nov 26, 1999·The New England Journal of Medicine·R Mayeux, M Sano
Apr 24, 1999·BMJ : British Medical Journal·T Bayer
May 23, 2002·Journal of Clinical Pharmacology·Joel MorganrothRavi Anand
Aug 7, 2002·Clinical Pharmacokinetics·Michael W JannGary W Small
Jul 16, 2003·Clinical Therapeutics·Bradley R WilliamsMark A Gill
May 26, 2011·Expert Opinion on Therapeutic Patents·M Jason Hatfield, Philip M Potter
May 5, 2001·Expert Opinion on Pharmacotherapy·A Desai, G Grossberg
May 20, 1999·The Annals of Pharmacotherapy·W J KrallN R Cutler
Mar 14, 2000·International Journal of Geriatric Psychiatry·G T GrossbergJ Veach
Sep 24, 2015·The Cochrane Database of Systematic Reviews·Jacqueline S BirksJohn Grimley Evans
May 12, 1998·Acta Neurologica Scandinavica·N R CutlerP Zolnouni
Nov 30, 2000·Current Treatment Options in Neurology·A S Schachter, K L Davis
Jun 13, 2003·Journal of the American Geriatrics Society·David S Geldmacher

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.